Bristol-Myers Squibb stock analysis
Bristol-Myers Squibb passes 5 of 8 fundamental tests, a score of 6/10. On the daily chart it is in a sideways range, RSI 44, 13% below its 52-week high: range-bound: no edge either way. Its own volatility puts the likely range at $55.18–$64.70 a month from now and $45.35–$78.73 in a year (68% bands).
Fundamentals 6/10
- Market cap
- $122.1 B
- P/E · forward
- 13.2 · 9.0
- PEG · P/B
- 16.6 · 5.5
- ROE · net margin
- +47% · +19%
- Revenue · earnings growth
- +6% · +153%
- Debt / equity
- 202%
- Dividend · beta
- 4.2% · 0.2
- Next results
- 29 Oct 2026
- ✓ ROE above 15%
- ✓ Net margin above 10%
- ✕ Revenue growing over 10%
- ✓ Earnings growing
- ✕ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✕ PEG under 2
Swing technicals (daily)
- Trend
- sideways · 50d above 200d
- RSI(14)
- 44
- 20 / 50 / 200-day avg
- $60.64 / $63.51 / $59.64
- 20-day breakout
- above $64.13 · below $56.15
- ATR(14)
- $1.79 (3.0% a day)
- 52-week range
- $42.52 – $68.64
- Return 3m · 6m · 1y
- -1% · -1% · +37%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $55.18 – $64.70 (-8% / +8%) |
| 3 mo | $52.05 – $68.59 (-13% / +15%) |
| 6 mo | $49.16 – $72.62 (-18% / +22%) |
| 1 year | $45.35 – $78.73 (-24% / +32%) |
Analysts (24): buy, mean target $65.63 (+10%)
From its own volatility (28% a year), no drift assumed: what its swings allow, not a forecast.
Bristol-Myers Squibb news · last two days
News lean: Neutral- 42h agoBristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool
- 3d agoBristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS SaysMT Newswires
- 3d agoHow Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) InvestorsSimply Wall St.
- 5d agoBristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on ItZacks
- 5d agoWhat Does Bristol-Myers Squibb Offer That Pfizer Does Not?Trefis
- 5d agoBMY Reports Mixed Phase III Trial Results, Stock DownZacks
- 6d agoBristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% RunYahoo Finance UK
- 6d agoWill Bristol-Myers Squibb stock avoid deeper losses amid ongoing seller pressure?tradersunion
- 6d agoBristol Myers Squibb (BMY) drops 4.3%: what the slide means for dividend investors24/7 Wall St.
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.